Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × regorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 92 Carcinoma, Hepatocellular 23 Neoplasm Metastasis 18 Neoplasms 15 Gastrointestinal Stromal Tumors 12 Rectal Neoplasms 10 Colonic Neoplasms 10 Glioblastoma 7 Liver Neoplasms 6 Stomach Neoplasms 5 Sarcoma 5 Ovarian Neoplasms 5 Melanoma 5 Sarcoma, Ewing 4 Osteosarcoma 4 Esophageal Neoplasms 4 Carcinoma, Renal Cell 4 Carcinoma, Non-Small-Cell Lung 4 Adenocarcinoma 4 Small Cell Lung Carcinoma 3 Rhabdomyosarcoma 3 Pancreatic Neoplasms 3 Leukemia, Myeloid, Acute 3 Colorectal Cancer Metastatic 3 Cholangiocarcinoma 3 Carcinoma, Transitional Cell 3 Carcinoma 3 Advanced Colorectal Cancer 3 Thyroid Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2

Interventions

Cyclophosphamide 133 Dexamethasone 111 Rituximab 72 fludarabine 65 Lenalidomide 61 Cytarabine 59 Gemcitabine 54 Bortezomib 50 fludarabine phosphate 49 pembrolizumab 46 venetoclax 45 Etoposide 44 Paclitaxel 43 Carboplatin 42 Cisplatin 41 pomalidomide 40 Peripheral Blood Stem Cell Transplantation 38 Filgrastim 37 Radiotherapy 35 Bevacizumab 33 Melphalan 31 Busulfan 31 Calcium Dobesilate 30 carfilzomib 28 Cyclosporine 28 Methotrexate 27 Azacitidine 26 Nivolumab 25 Mycophenolic Acid 25 Temozolomide 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03970447 2025-09-09

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡